Brooks Laboratories Intrinsic Value
Brooks Laboratories intrinsic value. Brooks Laboratories (BROOKS) median intrinsic value is ₹40.75 from 9 valuation models (range ₹18–₹82), vs current price ₹59.66 — -31.7% downside (Trading Above Calculated Value), margin of safety -46.4%. Compare with BROOKS fair value to assess whether the stock is under or overvalued.
BROOKS Valuation Methods Summary — DCF, Graham Number & P/E
Brooks Laboratories intrinsic value across 9 models vs current price ₹59.66 — upside/downside and value range per method. Read BROOKS dividend payout details for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹45.76 | ₹36.61 - ₹54.91 | -23.3% | EPS: ₹2.08, Sector P/E: 22x |
| Book Value Method | asset | ₹82.00 | ₹73.80 - ₹90.20 | +37.4% | Book Value/Share: ₹41.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹58.67 | ₹52.80 - ₹64.54 | -1.7% | Revenue/Share: ₹29.33, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹26.67 | ₹24.00 - ₹29.34 | -55.3% | EBITDA: ₹8.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹40.75 | ₹32.60 - ₹48.90 | -31.7% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹17.90 | ₹16.11 - ₹19.69 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹32.14 | ₹28.93 - ₹35.35 | -46.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹29.83 | ₹26.85 - ₹32.81 | -50.0% | ROE: 6.5%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹43.80 | ₹39.42 - ₹48.18 | -26.6% | EPS: ₹2.08, BVPS: ₹41.00 |
BROOKS Intrinsic Value vs Market Price — All Valuation Models
Brooks Laboratories fair value range ₹18–₹82 vs current market price ₹59.66 across 9 valuation models. For current market price and key ratios, visit Brooks Laboratories stock price NSE.
BROOKS Intrinsic Value Analysis — Undervalued or Overvalued?
Brooks Laboratories median intrinsic value ₹40.75, current price ₹59.66 — Trading Above Calculated Value by 31.7%, margin of safety -46.4%.
What is the intrinsic value of BROOKS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Brooks Laboratories (BROOKS) is ₹40.75 (median value). With the current market price of ₹59.66, this represents a -31.7% variance from our estimated fair value.
The valuation range spans from ₹17.90 to ₹82.00, indicating ₹17.90 - ₹82.00.
Is BROOKS undervalued or overvalued?
Based on our multi-method analysis, Brooks Laboratories (BROOKS) appears to be trading above calculated value by approximately 31.7%.
BROOKS Financial Health — Key Ratios vs Industry Benchmarks
Brooks Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.25 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 6.5% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.59x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
BROOKS Cash Flow Quality — Operating & Free Cash Flow
Brooks Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹9 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹3 Cr | ₹-20 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹-10 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-15 Cr | ₹-15 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-37 Cr | ₹-50 Cr | Negative Cash Flow | 3/10 |